Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort

Thrombosis and Haemostasis

Volumn 101, Issue 1, 2009, Pages 100-107

  Neville, Carolyn ^a   Rauch, Joyce ^a   Kassis, Jeannine ^b   Solymoss, Susan ^a   Joseph, Lawrence ^a,c   Belisle, Patrick ^a   Levine, Jerrold S ^d,e   Fortin, Paul R ^f,g,h  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF ILLINOIS   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Activated protein C resistance; Anti beta2 glycoprotein I; Antiphospholipid antibodies; Thrombosis; Von Willebrand factor

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; PHOSPHOLIPID ANTIBODY; VON WILLEBRAND FACTOR; AUTACOID; BIOLOGICAL MARKER;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTERY EMBOLISM; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE MARKER; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VEIN EMBOLISM; VEIN THROMBOSIS; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK; RISK ASSESSMENT; TIME; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; BIOLOGICAL MARKERS; BLOOD COAGULATION; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION MEDIATORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VASCULAR DISEASES;

EID: 60849130135     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-06-0384     Document Type: Article

References (34)

1. Kassis J, Neville C, Ranch J, et al. Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thromb Haemost 2004; 92: 1312-1319.
2. Rauch J, Tannenbaum M, Neville C, et al. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost 1998; 80: 936-941.
3. Levine JS, Subang R, Nasr SH, et al. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol 2006; 177: 6504-6516.
4. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
5. Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
6. Miyakis S, Lockshin MD, Atsumi X et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
7. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531-2536.
8. Vaarala O, Mantlari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-27.
9. Finazzi G, Brancaccio Y Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536.
10. Bili A, Moss AJ, Francis CW. et al. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients, Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000; 102: 1258-1263.
11. Brey RL, Abbott RD, Curb JD, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke 2001; 32: 1701-1706.
12. Janardhan V. Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 2004; 35: 736-741.
13. Toloza SM, Uribe AG, McGwin G, Jr., et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA), XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004: 50: 3947-3957.
14. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
15. Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke 2005; 36: 1490-1494,
16. Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-2782.
17. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178-1183.
18. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-oeelusive events in patients with ischemic stroke. J Am Med Assoc 2004; 291: 576-584.
19. Erkkila AT, Narvanen O, Lehto S. et al. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Ar-terioscler Thromb Vasc Biol 2000; 20: 204-209.
20. Heinzlef O, Abuaf N, Cohen A, et al. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J Neurol 2001;248:373-379.
21. Akimoto T, Kobayashi S, Tamura N, et al. Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 2005; 56: 601-609.
22. Ahmed E, Stegmayr B, Trifunovic J, et al. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke 2000; 31: 1289-1293.
23. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997;28: 1660-1665.
24. Calvo-Alen J, Toloza SMA, Fernandez M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) - XXV Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52: 2060-2068.
25. van Goor MP, Alblas CL, Leebeek FW, et al. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol Scand 2004; 109:410-415.
26. Wittkowsky AK, Downing .1, Blackburn J, et al. Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic. Thromb Haemost 2006; 96: 137-141.
27. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
28. Neville C, Ranch J, Kassis J, et al. Thromboembolic risk in patients with high litre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003; 90: 108-115.
29. Hudson M, Herr AL, Rauch J, et al. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies, J Rheumatol 2003; 30:2385-2391.
30. Neville C, Rauch J, Kassis .1, et al. The persistence of anticardiolipin antibodies is associated with an increased risk of the presence of lupus anticoagulant and anti-beta2-glycoprotein I antibodies. Rheumatology (Oxford) 2006; 45: 1116-1120.
31. Sanmarco M, Gayet S, Alessi MC, et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost 2007; 97: 949-954.
32. Tomas JF, Alberca I, Tabernero MD, et al. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1998; 25: 57-62.
33. Nojima J, Kuratsune H, Suehisa E, et al. Acquired activated protein C resistance is associated with the coexistence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118: 577-583.
34. Meesters EW, Hansen II, Spronk HM, et al. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 2007; 18:21-28.